Pluri and ZEO ScientifiX Form Strategic Partnership
The deal gives Pluri a 50% stake in ZEO, aiming to scale U.S. manufacturing for regenerative medicine by late 2026.
Updated on Oct. 26, 2026 in Biotech
Live Poll
Do you believe partnerships between biotech companies generally result in better medical treatment options?
Pluri and ZEO ScientifiX have announced a definitive strategic partnership involving an acquisition of a 50% ownership stake. The companies plan to integrate their respective cell technology and manufacturing infrastructure to expand regenerative medicine capabilities in the U.S.
Why it matters
This partnership aims to accelerate the commercialization of regenerative medicine and aesthetics products by combining proprietary cell-based intellectual property with existing biologics manufacturing frameworks.
Pluri maintains control over its intellectual property, which includes a portfolio of over 200 patents. The partnership grants ZEO rights to utilize Pluri's proprietary cell-manufacturing technology.
The players
Pluri
An Israel-based biotechnology firm focused on cell-based therapeutics and possessing a proprietary portfolio of over 200 patents.
ZEO ScientifiX
A biologics manufacturer and aesthetics company based at the Nova Southeastern University Center for Collaborative Research in Davie, Florida.
The details
The collaboration integrates Pluri's cell-culture technology with ZEO ScientifiX's established biologics manufacturing and commercial infrastructure. By pooling these resources, the companies intend to scale the production of regenerative medicine and aesthetic products. ZEO will issue common stock representing 50% of its total outstanding shares to Pluri to finalize the arrangement.
Timeline
October 26, 2026: Companies announced the definitive strategic partnership agreement.
Q4 2026: The transaction is expected to close.
The Tech Race
This deal accelerates the push to move regenerative therapies from research environments like the Nova Southeastern University Center for Collaborative Research into commercial-scale production. It follows a growing industry trend of matching specialized cell-tech startups with established biologics manufacturing infrastructure to speed up time-to-market.
The partnership is set to influence the availability of regenerative medicine and aesthetic therapies within the United States market. While the deal is scheduled to close in late 2026, specific commercial product release dates and pricing remain unannounced.
The takeaway
This partnership signals a shift toward consolidating manufacturing infrastructure to move advanced cell therapies toward market viability. Interested observers should monitor the Q4 2026 closing date for the official consolidation of financial reporting between the two entities.
What happens next
The transaction is expected to conclude in the fourth quarter of 2026, at which point ZEO ScientifiX's financial results will be integrated into Pluri's official financial statements.
Further reading
Explore more developments in the field of Biotech.
Live Poll
Do you believe partnerships between biotech companies generally result in better medical treatment options?
